Table II.
Cytokine genetic polymorphisms and risk of aggressive PCa stratified by race
| Gene-SNP location | Genotype | Caucasian Americans | African-Americans |
||
| High/low-intermediate aggressivenessa | Adjusted ORb (95% CI) | High/low-intermediate aggressiveness | Adjusted OR (95% CI) | ||
| IL1B−511 | CC | 34/180 | 1.00 | 1/12 | 1.00 |
| CT | 31/196 | 0.94 (0.55–1.61) | 6/25 | 9.48 (0.73–122.86) | |
| TT | 9/42 | 0.99 (0.42–2.31) | 6/21 | 6.55 (0.59–72.35) | |
| CT/TT | 40/238 | 0.95 (0.57–1.58) | 12/46 | 7.40 (0.72–76.48) | |
| IL1B−31 | TT | 32/179 | 1.00 | 1/12 | 1.00 |
| CC | 32/197 | 1.25 (0.55–2.86) | 6/23 | 6.64 (0.60–73.78) | |
| TC | 10/41 | 1.02 (0.59–1.75) | 6/22 | 11.33 (0.84–152.86) | |
| TC/CC | 42/238 | 1.06 (0.63–1.78) | 12/45 | 7.83 (0.75–81.22) | |
| ILB+3954 | CC | 45/244 | 1.00 | 8/46 | 1.00 |
| CT | 22/155 | 0.80 (0.46–1.40) | 4/9 | 3.62 (0.72–18.19) | |
| TT | 8/14 | 3.11 (1.20–8.06) | 1/3 | 3.07 (0.22–43.40) | |
| CT/TT | 30/169 | 1.00 (0.60–1.66) | 5/12 | 3.48 (0.80–15.11) | |
| IL10−1082 | AA | 14/110 | 1.00 | 5/16 | 1.00 |
| GA | 32/203 | 1.21 (0.60–2.43) | 7/35 | 0.70 (0.17–2.90) | |
| GG | 29/105 | 2.31 (1.13–4.72) | 1/7 | 0.68 (0.05–8.52) | |
| GG/GA | 61/308 | 1.58 (0.83–3.02) | 8/42 | 0.70 (0.18–2.78) | |
| IL10−819 | CC | 47/243 | 1.00 | 6/22 | 1.00 |
| CT | 18/131 | 0.69 (0.38–1.26) | 6/26 | 0.63 (0.15–2.70) | |
| TT | 5/30 | 0.95 (0.35–2.61) | 0/8 | NCc | |
| TT/CT | 23/161 | 0.74 (0.42–1.27) | 6/34 | 0.50 (0.12–2.10) | |
| IL10−592 | CC | 48/251 | 1.00 | 6/20 | 1.00 |
| AA | 6/31 | 1.13 (0.44–2.91) | 1/7 | 0.46 (0.04–5.29) | |
| CA | 20/140 | 0.73 (0.41–1.29) | 6/30 | 0.48 (0.12–2.01) | |
| CA/AA | 26/141 | 0.80 (0.47–1.35) | 7/37 | 0.48 (0.12–1.87) | |
| TNF−857 | CC | 64/349 | 1.00 | 12/52 | 1.00 |
| CT | 7/52 | 0.75 (0.32–1.74) | 0/4 | NC | |
| TT | 0/6 | NC | 0/0 | NC | |
| CT/TT | 7/58 | 0.68 (0.30–1.57) | 0/4 | NC | |
| TNF−238 | GG | 69/368 | 1.00 | 11/52 | 1.00 |
| AA | 0/35 | NC | 0/0 | NC | |
| GA | 6/35 | 0.90 (0.36–2.25) | 1/4 | 1.40 (0.13–15.75) | |
| GA/AA | 6/70 | 0.78 (0.32–1.93) | 1/4 | 1.40 (0.13–15.75) | |
| TNF−308 | GG | 47/291 | 1.00 | 11/50 | 1.00 |
| AA | 3/10 | 1.70 (0.44–6.53) | 0/1 | NC | |
| GA | 24/121 | 1.18 (0.69–2.05) | 2/7 | 0.87 (0.14–5.6) | |
| GA/AA | 27/131 | 1.22 (0.72–2.08) | 2/8 | 0.83 (0.13–5.32) | |
| IL6−598 | GG | 23/128 | 1.00 | 9/43 | 1.00 |
| AA | 9/79 | 0.68 (0.30–1.57) | 0/1 | NC | |
| GA | 38/176 | 1.19 (0.66–2.14) | 2/10 | 1.19 (0.18–7.70) | |
| GA/AA | 47/255 | 1.04 (0.59–1.81) | 2/11 | 1.19 (0.18–7.70) | |
| IL6+180 | GG | 22/123 | 1.00 | 10/43 | 1.00 |
| AA | 10/19 | 0.73 (0.32–1.65) | 0/2 | NC | |
| GA | 34/34 | 1.08 (0.59–1.97) | 2/34 | 1.71 (0.25–11.57) | |
| GA/AA | 44/53 | 0.97 (0.54–1.72) | 2/36 | 1.68 (0.25–11.32) | |
| IL6−174 | CC | 21/112 | 1.00 | 3/6 | 1.00 |
| CG | 34/163 | 1.08 (0.59–2.00) | 2/10 | 0.66 (0.05–8.92) | |
| GG | 19/126 | 0.77 (0.39–1.52) | 10/41 | 0.38 (0.05–3.13) | |
| CG/GG | 53/289 | 0.94 (0.54–1.64) | 12/51 | 0.41 (0.01–3.29) | |
| IL8+230 | GG | 19/98 | 1.00 | 3/15 | 1.00 |
| GT | 25/176 | 0.76 (0.40–1.46) | 7/23 | 1.13 (0.22–5.82) | |
| TT | 27/119 | 1.10 (0.57–2.13) | 2/17 | 0.43 (0.05–3.65) | |
| GT/TT | 52/295 | 0.90 (0.50–1.61) | 9/40 | 0.84 (0.18–3.97) | |
| IL8−47 | CC | 63/372 | 1.00 | 11/49 | 1.00 |
| CT | 7/10 | 3.81 (1.35–10.76) | 1/4 | 1.35 (0.12–14.97) | |
| TT | 1/5 | 1.29 (0.14–11.67) | 1/3 | 5.10 (0.32–81.48) | |
| CT/TT | 8/15 | 3.01 (1.20–7.56) | 2/7 | 2.19 (0.33–14.51) | |
| IL8−251TT | TT | 27/112 | 1.00 | 1/4 | 1.00 |
| AA | 16/87 | 0.78 (0.39–1.56) | 6/31 | 1.44 (0.10–19.95) | |
| TA | 22/154 | 0.65 (0.34–1.23) | 4/13 | 1.78 (0.13–25.12) | |
| TA/AA | 38/241 | 0.70 (0.40–1.23) | 10/44 | 1.59 (0.13–19.79) | |
NC, non-convergent.
a
Number of subjects with high aggressive PCa compared with number of subjects with low or intermediate aggressive PCa.
b
Adjusted for age, smoking history and history of BPH.